InvestSMART

Australian Clinical Labs Limited (ASX: ACL) - Announcements

Current share price for ACL : $2.770 0.02 (0.73%)+

ASX company news and announcements for Australian Clinical Labs Limited (ACL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Australian Clinical Labs Limited (ACL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Australian Clinical Labs Limited (ACL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Australian Clinical Labs Limited (ACL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$517 Appendix 4C - Quarterly Commitments Report 10 Oct 2007 12:11PM $0.900 $2.770 risen by 207.78%
$517 Preliminary Final Report 27 Aug 2007 1:58PM $0.800 $2.770 risen by 246.25%
$517 Appendix 4C - quarterly 31 Jul 2007 11:12AM $0.810 $2.770 risen by 241.98%
$517 Alchemia successfully completes capital raising 19 Jul 2007 9:56AM $0.895 $2.770 risen by 209.50%
$517 Trading Halt 18 Jul 2007 11:00AM $0.880 $2.770 risen by 214.77%
$517 Granted key HyACT patent in Europe 6 Jul 2007 10:02AM $0.955 $2.770 risen by 190.05%
$517 Arixtra Receives Positive Opinion in EU for Treatment of ACS 26 Jun 2007 12:22PM $0.930 $2.770 risen by 197.85%
$517 Clinical Appendix - Positive Final Data from Phase II Trial 29 May 2007 11:36AM $1.085 $2.770 risen by 155.30%
$517 Alchemia announces positive final data from HyCAMP Phase II 29 May 2007 11:35AM $1.085 $2.770 risen by 155.30%
$517 Commitments Test Entity - Third Quarter Report 27 Apr 2007 8:34AM $1.200 $2.770 risen by 130.83%
$517 New Marketing and Manufacturing Partner Synthetic Heparin 26 Apr 2007 9:40AM $1.150 $2.770 risen by 140.87%
$517 Preliminary positive efficacy data HyCAMP Phase II trial 26 Apr 2007 9:40AM $1.150 $2.770 risen by 140.87%
$517 Trading Halt 23 Apr 2007 9:36AM n/a $2.770 n/a
$517 Half Yearly Report & Half Year Accounts 26 Feb 2007 11:45AM $1.020 $2.770 risen by 171.57%
$517 Arixtra Sales Rise by 143% 9 Feb 2007 12:40PM $1.190 $2.770 risen by 132.77%
$517 US FDA issue approval letter for Arixtra 5 Feb 2007 11:54AM $1.100 $2.770 risen by 151.82%
$517 Commitments Test Entity - Second Quarter Report 31 Jan 2007 11:10AM $1.150 $2.770 risen by 140.87%
$517 Response to ASX Query 29 Jan 2007 1:27PM $1.015 $2.770 risen by 172.91%
$517 Commitments Test Entity - First Quarter Report 20 Oct 2006 9:19AM $0.655 $2.770 risen by 322.90%
$517 Arixtra Receives Priority Review by FDA 4 Oct 2006 9:33AM $0.670 $2.770 risen by 313.43%
$517 Satisfactorily resolves impasse with APP 27 Sep 2006 1:53PM $0.685 $2.770 risen by 304.38%
$517 Preliminary Final Report & Full Year Accounts 4 Sep 2006 5:03PM $0.590 $2.770 risen by 369.49%
$517 Synthetic Heparin Program Partnership with APP under review 28 Aug 2006 9:33AM $0.575 $2.770 risen by 381.74%
$517 Trading Halt 24 Aug 2006 9:28AM n/a $2.770 n/a
$517 Commitments Test Entity - Fourth Quarter Report 1 Aug 2006 8:52AM $0.960 $2.770 risen by 188.54%

951 - 975 of 1017 results

Page 39 of 41

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.